Clementia keeps the biotech IPO party going with $120M play on an upsized offering
David Mott, the prolific New Enterprise Associates general partner, has another successful IPO under his belt for another one of his portfolio companies.
Quebec-based Clementia Pharmaceuticals $CMTA, which picked up a failed drug from Roche and repurposed it for a pair of ultra-rare diseases, raised $120 million today after pricing 8 million shares at $15.
That rings the bell at the top of the range with an upsized offering, just the latest indicator that the IPO window remains open for the right biotechs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.